采浆量增长，品种扩充，并购频繁……当规模的"面子"与盈利的"里子"出现错位，在华润入主四年的大 象转身之后，博雅生物距离真正的"血制品王者"，究竟还差哪一块拼图？ 撰文｜Erin Kathy 春节前，国药旗下血制品龙头天坛生物的一则人事公告引发市场关注，业务型掌舵者杨汇川辞任董事 长，由拥有高级会计师背景的梁红军接棒。这被行业视为一家央企血制品核心平台在行业下行周期中的 主动转身。 年后，华润医药旗下血制品平台博雅生物，也迎来高管层面的更迭，上任不到一年的总裁任辉辞职。 两起人事调整，既有共性，也有差异，但背景高度一致，行业正集体处在市场下行周期的阵痛之中。从 业绩层面看，两家公司面临的是同一道难题。集采扩围、DRG/DIP支付改革、医保控费、重点监控合理 用药政策持续推进，血液制品在部分临床场景中的处方量受到压缩；需求端景气度回落叠加市场竞争加 剧，直接传导至毛利率承压。 当行业周期下行，利润空间被压缩，管理层更替往往意味着企业试图重构增长逻辑。天坛与博雅，都在 寻找那位能带领企业穿透周期、实现转身的"关键先生"。 寻找关键先生 博雅生物的调整也具有其特殊性。 它不仅是行业压力下的主动换血，更是华润医药入主 ...

摘要 ■ 投资逻辑 基于大模型对券商年度展望的全面解析 每年的年底到年初，各券商会密集发布关于总量、行业等年度报告。对投资者而言，难以整合大量研报信息从而提取共识点，此外分歧点也同样缺乏量化 对比。大模型工具的出现解决了这一难点，大模型可以帮助分析师快速完成研报数据预处理、观点精准抓取与分类；大模型通过确定共识点与分歧点的判 定规则，系统整合分散观点，量化呈现各券商对板块不同观点的支持率，清晰核心分歧维度。本次研究以大模型为核心分析工具，全面剖析2026年各大板 块年度展望，梳理宏观、策略、固收及七大细分行业的共识与分歧，为投资者提供高效精准的决策参考。 总量观点总结 对于总量观点，我们分别从宏观经济、年度策略、固定收益三个方面分别剖析了各券商分析师的年度展望。 在宏观经济方面，大多数券商认为随着"十五五"政策发力，2026年GDP目标为5%左右；CPI、PPI从低位逐步修复，国内通货膨胀的压力得到缓解；货币 政策维持适度宽松基调，流动性保持合理充裕；财政政策延续积极取向，赤字率维持合理高位；出口保持稳健，贸易顺差维持历史较高水平；国外环境虽 然出现波动，但整体风险可控。 作者：高智威、许坤圣 在年度策略方面 ...

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the supply-demand relationship will gradually improve, leading to performance recovery for companies in this sector [10][34]. Core Insights - The blood products industry is characterized by a clear long-term growth trajectory, supported by a favorable regulatory environment for plasma collection and an expanding product range among companies [12][34]. - Short-term performance has been impacted by supply-demand mismatches, with a notable decline in profitability observed in 2025 due to excess supply and price reductions [19][36]. - The report highlights the importance of white albumin and immunoglobulin (IVIG) as core products, with a stable demand expected despite recent price pressures [33][34]. Summary by Sections Market Review - The report notes a decline of 0.85% in the medical index, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 sectors [6]. - The top-performing stocks in the medical sector include Aidi Te, Zhendai Medical, and Olin Bio, while the worst performers include Beixin Life and Huayuan Bio [6]. Industry and Stock Events - The report emphasizes the recovery of plasma collection activities post-pandemic, which has led to increased supply and a shift in the market dynamics for blood products [19][26]. - The report identifies key companies to watch, including Tian Tan Biological and Bo Ya Biological, as they are expected to benefit from the industry's growth [12][34]. Overall Perspective and Investment Themes - The report suggests focusing on innovative drugs, medical devices, and the blood products sector, highlighting the potential for significant growth driven by domestic differentiation and international expansion [10][12]. - The report also discusses the ongoing consolidation in the industry, particularly among state-owned enterprises, which may enhance market concentration and operational efficiencies [46]. Supply and Demand Dynamics - The report indicates that the supply of blood products is expected to tighten in 2026 due to a slowdown in plasma collection growth and a decrease in imported white albumin supply [30][34]. - Demand for white albumin remains robust, with sales showing signs of stabilization despite recent challenges [33][34]. Future Outlook - The report anticipates a gradual return to a balanced supply-demand relationship in the blood products industry, which could lead to improved financial performance for key players [34][36]. - The potential for new product introductions and market expansions is highlighted as a significant driver for future growth in the sector [12][34].

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the sector has clear long-term growth potential due to increasing supply and demand elasticity [12][19][36]. Core Insights - The blood products industry is expected to benefit from a more relaxed approval process for plasma collection stations during the 14th Five-Year Plan, leading to increased production capacity and a diverse range of products [12][19]. - The report highlights a significant shift in the industry from a supply surplus to a supply-demand balance, with expectations for improved performance in 2026 as supply constraints tighten and demand remains stable [36][34]. - Key companies to watch include TianTan Biotech, BoYa Bio, and HuaLan Bio, which are expected to see performance improvements as the market stabilizes [12][36]. Summary by Sections Market Review - The report notes that the CITIC pharmaceutical index fell by 0.85%, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 primary industries [6]. - The top-performing stocks in the sector included AidiTe and ZhenDe Medical, while stocks like BeiXin Life and HuaYuan Bio faced significant declines [6][12]. Industry and Stock Events - The blood products sector has experienced a prolonged adjustment period, with a cumulative decline of 18.1% since early 2025, significantly underperforming the broader pharmaceutical sector [16]. - The report indicates that the performance of major blood product companies has varied, with some like WeiGuang Bio and HuaLan Bio performing better than the sector average [16]. Overall Perspective and Investment Themes - The report emphasizes the transition from a quantity-driven to a quality-driven approach in the innovative drug sector, suggesting a focus on differentiated products and international expansion [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, with companies like MaiRui and LianYing expected to benefit from ongoing upgrades [10]. - The report also highlights the importance of the CXO and life sciences services sectors, predicting a recovery in domestic investment and a return to high growth rates [10]. Blood Products - The blood products industry is characterized by a clear growth trajectory, with both supply and demand expected to show significant elasticity [12][19]. - The report suggests that the industry will see improved performance due to a combination of increased plasma collection and a tightening supply situation, which is expected to stabilize prices and enhance profitability for key players [36][34].

Core Insights - MSCI announced its quarterly index adjustments for February 2026, including the addition of 37 stocks to the MSCI China Index, reflecting international capital's recognition of China's growth in strategic emerging technology sectors such as AI and autonomous driving [1][3]. Group 1: New Additions - The newly added stocks include companies from various sectors such as technology, energy, and finance, with notable inclusions like Pony.ai (02026), Silver Holdings (601212.SH), and Leo Group (002131.SZ) [1][3]. - Among the new additions, four are Hong Kong stocks, including Pony.ai, SenseTime (00020), and Hesai Technology (02525), which represent the core technology chain for autonomous driving [1][3]. - The adjustment is expected to lead to passive fund inflows into the newly added stocks around the effective date of February 27 [1][3]. Group 2: Stocks Removed - A total of 16 stocks were removed from the index, primarily from traditional sectors such as real estate, finance, and automotive, including Zhejiang Expressway (00576) and China Communications Services (00552) [4][5]. - The removal of these stocks indicates a shift in market dynamics and a focus on enhancing the index's representation and liquidity [4][5].

Core Viewpoint - The company has announced a change in the project quality reviewer for its 2025 financial report audit, with Huang Jiacai replacing Wei Jun due to work arrangement adjustments [2][4]. Group 1: Announcement of Change - The company received a letter from Tianjian Accounting Firm regarding the change of the project quality reviewer [2]. - Wei Jun was originally appointed as the project quality reviewer for the 2025 financial report audit, but he has been replaced by Huang Jiacai [2]. Group 2: New Project Quality Reviewer's Background - Huang Jiacai has been a certified public accountant since July 2005 and has been practicing at Tianjian Accounting Firm since then [3]. - Huang Jiacai has not violated any independence requirements or faced any criminal or administrative penalties in the last three years [3]. Group 3: Impact of the Change - The transition of responsibilities during this change has been orderly, and it will not adversely affect the company's 2025 financial report audit and internal control audit [4].

Group 1 - The company TianTan Biological announced a change in the project quality reviewer for its 2025 financial statement audit [2] - TianJian Accounting Firm appointed Mr. Huang JiaCai to replace Mr. Wei Jun as the project quality reviewer due to Mr. Wei's work schedule adjustment [2] - The change pertains to the internal control audit of the financial report for the end of 2025 [2]

证券代码：600161 证券简称：天坛生物 公告编号：2026-004 一、本次变更项目质量复核人的情况 天健会计师事务所作为公司 2025 年度财务报表和 2025 年末财务报告内部控制审计 机构，原委派韦军先生作为公司 2025 年度财务报表审计报告和 2025 年末财务报告内部 控制审计报告的项目质量复核人。由于韦军先生工作安排调整，现委派黄加才先生接替 韦军先生作为项目质量复核人。变更后的项目质量复核人为黄加才先生。 二、新任项目质量复核人的基本情况 黄加才先生 2005 年 7 月成为中国注册会计师，自 2005 年 7 月开始在天健会计师事 务所执业。黄加才先生不存在违反《中国注册会计师独立性准则第 1 号——财务报表审 计和审阅业务对独立性的要求》和中国注册会计师职业道德守则有关独立性要求的情 形，最近三年未曾因执业行为受到过刑事处罚、行政处罚、监督管理措施和纪律处分。 三、本次变更对公司的影响 本次变更过程中相关工作安排已有序交接，变更事项不会对公司 2025 年度财务报 表审计和 2025 年末财务报告内部控制审计工作产生不利影响。 北京天坛生物制品股份有限公司 关于审计机构变更项目质量复核 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]